Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|9|2|151-177

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.9, Iss.2, 2009-06, pp. : 151-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

By  

Current Cancer Drug Targets, Vol. 16, Iss. 9, 2016-10 ,pp. : 755-764

Bentham Science Publishers

Access to resources Recommend Favorite

Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer

By  

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-02 ,pp. : 31-40

Bentham Science Publishers

Access to resources Recommend Favorite

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors

By Muller Alexander J   Malachowski William P   Prendergast George C  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 831-849

Informa Healthcare

Access to resources Recommend Favorite

The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer

By  

Current Medicinal Chemistry, Vol. 18, Iss. 15, 2011-05 ,pp. : 2263-2271

Bentham Science Publishers

Access to resources Recommend Favorite

How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation

By  

Current Drug Metabolism, Vol. 8, Iss. 3, 2007-04 ,pp. : 217-223

Bentham Science Publishers

Access to resources Recommend Favorite